P/E ratio for Repligen (RGEN)

P/E ratio history for Repligen from 2001 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Pfizer PFE	19.2	-86.59%	🇺🇸 USA
Thermo Fisher Scientific TMO	25.5	-82.23%	🇺🇸 USA
General Electric GE	43.7	-69.57%	🇺🇸 USA
Bristol-Myers Squibb BMY	15.2	-89.43%	🇺🇸 USA
Sangamo Therapeutics SGMO	-0.3864	-100.27%	🇺🇸 USA
Novavax NVAX	3.33	-97.68%	🇺🇸 USA
Neurocrine Biosciences NBIX	23.6	-83.56%	🇺🇸 USA
Bio-Techne TECH	81.6	-43.13%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	39.1	-72.78%	🇺🇸 USA
Charles River Laboratories CRL	-62.7	-143.70%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.